

# NHL: Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_

Line of Therapy: \_\_1<sup>st</sup> Line \_\_2<sup>nd</sup> Line \_\_3<sup>rd</sup> Line \_\_3<sup>rd</sup> Line+ \_\_Maint ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

Leukemia Stage: \_\_NS (No stage) \_\_Recurrent

Biomarkers/Characteristics: (select all that apply)

11q deletion: \_\_Absent \_\_Present

17p deletion: \_\_Absent \_\_Present

CD20 Status: \_\_Negative \_\_Positive

TP53 status: \_\_Mutation absent \_\_Mutation present

## First Line of Therapy (1<sup>st</sup> Line) | With 17p Deletion

Ibrutinib (Imbruvica)

## First Line of Therapy (1<sup>st</sup> Line) | Without 17p Deletion

**BR:** bendamustine (Bendeka, Treanda) and rituximab (Rituxan)

**FCR:** fludarabine (Fludara), cyclophosphamide, and rituximab (Rituxan)

Ibrutinib (Imbruvica)

Obinutuzumab (Gazyva) and chlorambucil (Leukeran)

## Second and Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | With 17p Deletion

Ibrutinib (Imbruvica)

Idelalisib (Zydelig)

Idelalisib (Zydelig) and rituximab (Rituxan)

## Second and Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | Without 17p Deletion

**BR:** bendamustine (Bendeka, Treanda) and rituximab (Rituxan)

Ibrutinib (Imbruvica)

Idelalisib (Zydelig)

Idelalisib (Zydelig) and rituximab (Rituxan)

Primary treatment for CLL should be initiated in accordance with the guidelines established by the Working Group on CLL

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

